Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Hohmann, M
Hypotonie, orthostatische Hypotonie und V.-Cava-KompressionssyndromWerner Rath, Ulrich Gembruch, Stephan Schmidt (Hrsg). Geburtshilfe und Perinatalmedizin. 2. Aufl. Stuttgart: Georg Thieme Verlag 2011
Albrich, S; Laterza, R; Skala, C et al.
Impact of mode of delivery on levator morphology: a prospective observational study with three-dimensional ultrasound early in the postpartum periodBJOG. 2011 S. 1-9
Skala, CE; Renezeder, K; Albrich, S et al.
Mesh complications following prolapse surgery: management and outcomeEUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY. Bd. 159. H. 2. 2011 S. 453-456
Kantelhardt, EJ; Vetter, M; Spinda, K et al.
Molecular types, uPA/PAI-1, clinical and pathological features in node-negative breast cancer: Distribution within the clinical trial NNBC 3-Europe compared to a single-institution cohortBREAST. Bd. 20. 2011 S. S38-S38
Schrutka, L; Laterza, R; Albrich, S et al.
Pelvic Floor Dysfunction after levator trauma 1 year after delivery. A prospective case-control studyInt Urogynecol J. Bd. 22. H. S1. 2011 S. Abs 124
Untch, M; Fasching, PA; Konecny, GE et al.
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbepoetin alfa in primary breast cancer-results at the time of surgeryANNALS OF ONCOLOGY. Bd. 22. H. 9. 2011 S. 1988-1998
Untch, M; von Minckwitz, G; Konecny, GE et al.
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosisANNALS OF ONCOLOGY. Bd. 22. H. 9. 2011 S. 1999-2006
Kantelhardt, EJ; Vetter, M; Schmidt, M et al.
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 x FEC versus 3 x FEC/3 x DocetaxelBMC CANCER. Bd. 11. 2011 S. -
Bohm, D; Keller, K; Wehrwein, N et al.
Serum proteome profiling of primary breast cancer indicates a specific biomarker profileONCOLOGY REPORTS. Bd. 26. H. 5. 2011 S. 1051-1056
Skala, CE; Petry, IB; Albrich, S et al.
The effect of genital and lower urinary tract symptoms on steroid receptor expression in women with genital prolapseINTERNATIONAL UROGYNECOLOGY JOURNAL. Bd. 22. H. 6. 2011 S. 705-712